Latus Bio closed a $97 million Series A to advance a therapeutics pipeline built around novel AAV capsid variants, funding operations through milestones tied to early clinical data. The company said proceeds will support its Huntington’s disease program LTS-201 and its CLN2 gene therapy program LTS-101. The financing positions the startup to generate first clinical signals for programs intended to broaden delivery performance relative to earlier-generation capsids. Latus expects initial clinical data tied to its two most advanced programs by milestone checkpoints. For gene therapy investors, the round highlights continuing capital appetite for capsid engineering approaches and for companies seeking to differentiate delivery properties rather than only target biology.